Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ·Healthcare·Biotechnology
$303.44
-1.64%
Mkt Cap $41.24B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 12, 2026 | $1.15B | $1.10B | -4.53% | $1.16 | $0.82 | -29.31% | — | — |
| Q4 2025 Oct 30, 2025 | $959.40M | $1.25B | +30.19% | $0.56 | $2.90 | +416.93% | — | — |
| Q3 2025 Jul 31, 2025 | $662.87M | $773.69M | +16.72% | -$0.54 | $0.32 | +158.85% | — | — |
| Q2 2025 May 1, 2025 | $585.14M | $594.19M | +1.55% | -$0.89 | -$0.01 | +98.88% | — | — |
| Q1 2025 Feb 13, 2025 | $582.61M | $593.17M | +1.81% | -$0.62 | $0.06 | +109.68% | — | — |
| Q4 2024 Oct 31, 2024 | $532.91M | $500.92M | -6.00% | -$0.92 | -$0.50 | +45.45% | — | — |
| Q3 2024 Aug 1, 2024 | $447.22M | $659.83M | +47.54% | -$1.07 | $0.56 | +152.34% | — | — |
| Q2 2024 May 2, 2024 | $428.01M | $494.33M | +15.50% | -$1.12 | -$0.16 | +85.71% | — | — |
| Q1 2024 Feb 15, 2024 | $442.90M | $439.72M | -0.72% | -$1.20 | -$1.10 | +8.33% | — | — |
| Q4 2023 Nov 2, 2023 | $401.03M | $750.53M | +87.15% | -$1.34 | $1.15 | +185.82% | — | — |
| Q3 2023 Aug 3, 2023 | $350.51M | $318.75M | -9.06% | -$1.72 | -$2.21 | -28.49% | — | — |
| Q2 2023 May 4, 2023 | $312.26M | $319.29M | +2.25% | -$1.97 | -$1.40 | +28.93% | — | — |
| Q1 2023 Feb 23, 2023 | $313.13M | $335.04M | +6.99% | -$2.13 | -$1.68 | +21.13% | — | — |
| Q4 2022 Oct 27, 2022 | $291.66M | $264.31M | -9.38% | -$1.86 | -$3.32 | -78.49% | — | — |
| Q3 2022 Jul 28, 2022 | $255.56M | $224.82M | -12.03% | -$1.62 | -$2.29 | -41.36% | — | — |
| Q2 2022 Apr 28, 2022 | $240.95M | $213.26M | -11.49% | -$1.93 | -$2.00 | -3.63% | — | — |
| Q1 2022 Feb 10, 2022 | $233.61M | $258.54M | +10.67% | -$1.47 | -$2.16 | -46.94% | — | — |
| Q4 2021 Oct 28, 2021 | $219.69M | $187.63M | -14.59% | -$1.51 | -$1.72 | -13.91% | — | — |
| Q3 2021 Aug 3, 2021 | $220.55M | $220.55M | +0.00% | -$1.57 | -$1.61 | -2.55% | — | — |
| Q2 2021 Apr 29, 2021 | $169.04M | $177.57M | +5.04% | -$1.75 | -$1.71 | +2.29% | — | — |